[18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 3, 2003, Pages 147-153

  Kamel, Ehab M ^a   Wyss, Matthias T ^a   Fehr, Mathias K ^a   Von Schulthess, Gustav K ^a   Goerres, Gerhard W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Breast cancer; FDG PET; Recurrence; Tumor marker

Indexed keywords

CA 15-3 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; APPARATUS; ARTICLE; BREAST CANCER; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EVALUATION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SECOND CANCER; SENSITIVITY AND SPECIFICITY;

EID: 0038583761     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0424-z     Document Type: Article

References (28)

1. van Dongen JA, Voogd AC, Fentiman IS, et al (2000) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 92:1143-1150
2. Probstfeld MR, O'Connell TX (1989) Treatment of locally recurrent breast carcinoma. Arch Surg 124:1127-1129
3. Schwaibold F, Fowble BL, Solin LJ, Schultz DJ, Goodman RL (1991) The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 21:299-310
4. Avril N, Rose CA, Schelling M, et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495-3502
5. Wahl RL (2001) Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol 36:250-260
6. Beggs D, Hain F, Curran M, O'Doherty J (2002) FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med 29:542-546
7. Fleiss JL (1981) The measurement of interrater agreement. In: Fleiss JL (ed) Statistical methods for rates and proportions, 2nd edn. Wiley, Canada, pp 212-236
8. Fortin A, Larochelle M, Laverdiere J, Lavertu S, Tremblay D (1999) Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 17:101-109
9. Silvestrini R, Daidone MG, Luisi A, et al (1995) Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13:697-704
10. Jensen EV, Cheng G, Palmieri C, et al (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 98:15197-15202
11. Avril N, Menzel M, Dose J, et al (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42:9-16
12. Revillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791-808
13. Kim TS, Moon WK, Lee DS, et al (2001) Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 25:829-834
14. Bender H, Kirst J, Palmedo H, et al (1997) Value of 18fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17:1687-1692
15. Faneyte IF, Rutgers EJ, Zoetmulder FA (1997) Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer 80:886-891
16. Hathaway PB, Mankoff DA, Maravilla KR, et al (1999) Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 210:807-814
17. Ahmad A, Barrington S, Maisey M, Rubens RD (1999) Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 79:478-482
18. Hoffman EJ, Huang SC, Phelps ME (1979) Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 3:299-308
19. Freifelder R, Karp JS (1997) Dedicated PET scanners for breast imaging. Phys Med Biol 42:2463-2480
20. Eubank WB, Mankoff DA, Takasugi J, et al (2001) 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19:3516-3523
21. Ohta M, Tokuda Y, Suzuki Y, et al (2001) Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22:875-879
22. von Schulthess GK, Meier N, Stumpe KD (2001) Joint accumulations of FDG in whole body PET scans. Nuklearmedizin 40:193-197
23. Stumpe KD, Zanetti M, Weishaupt D, Hodler J, Boos N, Von Schulthess GK (2002) FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR imaging. AJR Am J Roentgenol 179:1151-1157
24. Diel IJ, Solomayer EF, Costa SD, et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363
25. Larcos G, Maisey MN (1996) FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 17:197-198
26. Russell EJ, Geremia GK, Johnson CE, et al (1987) Multiple cerebral metastases: detectability with Gd-DTPA-enhanced MR imaging. Radiology 165:609-617
27. Kokko R, Holli K, Hakama M (2002) Ca 15-3 in the follow-up of localised breast cancer, a prospective study. Eur J Cancer 38:1189-1193
28. Bakheet SM, Powe J, Kandil A, Ezzat A, Rostom A, Amartey J (2000) F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med 25:100-103